Globus Medical sank -1.4% this morning, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Globus Medical has logged a -12.0% 52 week change, compared to 23.0% for the S&P 500
-
GMED has an average analyst rating of buy and is -21.2% away from its mean target price of $66.36 per share
-
Its trailing earnings per share (EPS) is $2.01, which brings its trailing Price to Earnings (P/E) ratio to 26.0. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $2.59 and its forward P/E ratio is 20.2
-
The company has a Price to Book (P/B) ratio of 2.65 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 6.2, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
GMED has reported YOY quarterly earnings growth of 7.5% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $252.52 Million and the average free cash flow growth rate is 0.0%
-
Globus Medical's revenues have an average growth rate of 0.0% with operating expenses growing at -16.5%. The company's current operating margins stand at 23.1%